For patients with metastatic disease, immune-checkpoint inhibitors and BRAF/MEK inhibitors remain valid therapeutic options, with superior overall response rates than conventional chemotherapy [63]. This evidence concerns the gene MAP2K7 and metastatic neoplasm.